Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria Jose Soler

Showing results (1-10 of 76) with videos related to

Pageof 8
Sort By:
Clinical Kidney Journal|April 24, 2026
Targeting HIF2-PTHrP axis in kidney cancer: a paradigm shift in therapy?Eva Pella, Maria Jose Soler
Diabetes|December 1, 2010
ACE2 and diabetes: ACE of ACEs?Daniel Batlle, Maria Jose Soler, Minghao Ye
Clinical Kidney Journal|February 13, 2019
Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathyMontserrat Diaz, Irene Agraz, Maria Jose Soler
Experimental Physiology|January 29, 2008
Angiotensin-converting enzyme 2 and the kidneyMaria Jose Soler, Jan Wysocki, Daniel Batlle
Journal of the American Heart Association|August 23, 2023
Spot Urinary Sodium as a Biomarker of Diuretic Response in Acute Heart FailureNestor Oliva-Damaso, Julio Nuñez, Maria Jose Soler
The New England Journal of Medicine|October 29, 2025
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 DiabetesPaola Romagnani, Maria Jose Soler, Fernando C Fervenza
The New England Journal of Medicine|June 28, 2023
Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 VariantsMaria Jose Soler, Richard J Glassock, Fernando C Fervenza
Journal of the American Society of Nephrology : JASN|July 9, 2020
Authors' ReplyDaniel Batlle, Maria Jose Soler, Paul A Welling, et al.
Clinical Kidney Journal|April 3, 2023
Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solutionMehmet Kanbay, Sidar Copur, Berk Mizrak, et al.
Kidney International|January 20, 2024
The ASSESS-AKI study: urinary epidermal growth factor association with reduced risk of MAKE and ageMaria Jose Soler, Rodrigo Daza-Arnedo, Natalia Ramos, et al.
Pageof 8

Showing results (1-10 of 76) with videos related to

Sort By:
Pageof 8
Clinical Kidney Journal|April 24, 2026
Targeting HIF2-PTHrP axis in kidney cancer: a paradigm shift in therapy?Eva Pella, Maria Jose Soler
Diabetes|December 1, 2010
ACE2 and diabetes: ACE of ACEs?Daniel Batlle, Maria Jose Soler, Minghao Ye
Clinical Kidney Journal|February 13, 2019
Anti-phospholipase A2 receptor antibody and spontaneous remission in membranous nephropathyMontserrat Diaz, Irene Agraz, Maria Jose Soler
Experimental Physiology|January 29, 2008
Angiotensin-converting enzyme 2 and the kidneyMaria Jose Soler, Jan Wysocki, Daniel Batlle
Journal of the American Heart Association|August 23, 2023
Spot Urinary Sodium as a Biomarker of Diuretic Response in Acute Heart FailureNestor Oliva-Damaso, Julio Nuñez, Maria Jose Soler
The New England Journal of Medicine|October 29, 2025
Finerenone with Empagliflozin in Chronic Kidney Disease and Type 2 DiabetesPaola Romagnani, Maria Jose Soler, Fernando C Fervenza
The New England Journal of Medicine|June 28, 2023
Inaxaplin for Proteinuric Kidney Disease in Persons with Two APOL1 VariantsMaria Jose Soler, Richard J Glassock, Fernando C Fervenza
Journal of the American Society of Nephrology : JASN|July 9, 2020
Authors' ReplyDaniel Batlle, Maria Jose Soler, Paul A Welling, et al.
Clinical Kidney Journal|April 3, 2023
Intravenous fluid therapy in accordance with kidney injury risk: when to prescribe what volume of which solutionMehmet Kanbay, Sidar Copur, Berk Mizrak, et al.
Kidney International|January 20, 2024
The ASSESS-AKI study: urinary epidermal growth factor association with reduced risk of MAKE and ageMaria Jose Soler, Rodrigo Daza-Arnedo, Natalia Ramos, et al.
Pageof 8